litlas
ログインアカウント作成

Éric Raymond

1996–2025 年に発表

別表記
Eric Raymond
102
論文数
24,837
被引用数
79
h 指数
101
i10 指数

被引用数

Éric Raymond の年別被引用数1984 年: 被引用 2 件1994 年: 被引用 1 件1996 年: 被引用 1 件1998 年: 被引用 15 件1999 年: 被引用 32 件2000 年: 被引用 46 件2001 年: 被引用 52 件2002 年: 被引用 87 件2003 年: 被引用 110 件2004 年: 被引用 115 件2005 年: 被引用 157 件2006 年: 被引用 145 件2007 年: 被引用 186 件2008 年: 被引用 208 件2009 年: 被引用 247 件2010 年: 被引用 227 件2011 年: 被引用 211 件2012 年: 被引用 186 件2013 年: 被引用 248 件2014 年: 被引用 258 件2015 年: 被引用 254 件2016 年: 被引用 247 件2017 年: 被引用 254 件2018 年: 被引用 227 件2019 年: 被引用 744 件2020 年: 被引用 743 件2021 年: 被引用 697 件2022 年: 被引用 446 件2023 年: 被引用 292 件2024 年: 被引用 447 件2025 年: 被引用 237 件2026 年: 被引用 3 件1985〜1993 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,382 件、この内訳の 23.5%中国: 引用元論文 1,114 件、この内訳の 11%イタリア: 引用元論文 715 件、この内訳の 7.1%フランス: 引用元論文 608 件、この内訳の 6%イギリス: 引用元論文 551 件、この内訳の 5.4%ドイツ: 引用元論文 506 件、この内訳の 5%スペイン: 引用元論文 351 件、この内訳の 3.5%日本: 引用元論文 321 件、この内訳の 3.2%オランダ: 引用元論文 287 件、この内訳の 2.8%カナダ: 引用元論文 269 件、この内訳の 2.6%インド: 引用元論文 258 件、この内訳の 2.5%韓国: 引用元論文 239 件、この内訳の 2.4%
0%23.5%その他 25%

機関

分野

  • Medicine64.4%
  • Biochemistry, Genetics and Molecular Biology24.9%
  • Immunology and Microbiology3.9%
  • Chemistry1.2%
  • Materials Science1.1%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • その他3.6%

トピック

  • Neuroendocrine Tumor Research Advances4.1%
  • Hepatocellular Carcinoma Treatment and Prognosis4%
  • Lung Cancer Research Studies3.6%
  • PI3K/AKT/mTOR signaling in cancer2.7%
  • Pancreatic and Hepatic Oncology Research2.5%
  • Cancer Mechanisms and Therapy2.2%
  • その他80.9%

共著者

全論文

検索で開く
  1. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

    著者: Jianming Xu, Ken Kato, Eric Raymond, Richard Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jiménez‐Fonseca, Chen‐Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H. Yoon - The Lancet Oncology 2023 被引用: 291

  2. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

    著者: Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski - New England Journal of Medicine 2011 被引用: 2,547

  3. Targeting the TGFβ pathway for cancer therapy

    著者: Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Romain Cohen, Jérôme Cros, Sandrine Faivre, Éric Raymond, Armand de Gramont - Pharmacology & Therapeutics 2014 被引用: 615

  4. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

    著者: Sonia Brun, Eloïne Bestion, Éric Raymond, Firas Bassissi, Zuzana Macek Jílková, Soraya Mezouar, Madani Rachid, Marie Novello, Jennifer Tracz, Ahmed Hamaï, Gilles Lalmanach, Lise Vanderlynden, Raphaël Legouffe, Jonathan Stauber, Thomas Schubert, Maximilian G. Plach, Jérôme Courcambeck, Cyrille Drouot, Guillaume Jacquemot, Cindy Serdjebi, Gaël S. Roth, Jean‐Pierre Baudoin, Christelle Ansaldi, Thomas Decaens, Philippe Halfon - Autophagy 2021 被引用: 86

  5. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    著者: M. Caplin, Éric Baudin, Piero Ferollà, Pier Luigi Filosso, Mariano Garcı́a-Yuste, Eric Lim, Kjell Öberg, Giuseppe Pelosi, Aurel Perren, Roberta Rossi, William D. Travis, D.K. Bartsch, Jaume Capdevila, Frederico Costa, Jarosław B. Ćwikła, Wouter W. de Herder, Gianfranco Delle Fave, Barbro Eriksson, Massimo Falconi, Diego Ferone, David J. Gross, Ashley Grossman, Tetsuhide Ito, Robert T. Jensen, Gregory Kaltsas, Fahrettin Keleştimur, Réza Kianmanesh, Ulrich Knigge, Beata Kos‐Kudła, Eric P. Krenning, Emmanuel Mitry, M. Nicolson, Juan Manuel O’Connor, Dermot O’Toole, Ulrich-Frank Pape, Marianne Pavel, John Ramage, Éric Raymond, Guido Rindi, Andrea Rockall, Philippe Ruszniewski, Ramón Salazar, Aldo Scarpa, Eva Sedláčková, Anders Sundin, Christos Toumpanakis, Marie‐Pierre Vullierme, Wolfgang Weber, Bertram Wiedenmann, Zeng Zheng-Pei - Annals of Oncology 2015 被引用: 699

  6. Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

    著者: Mohamed Bouattour, Éric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre - Hepatology 2017 被引用: 261

  7. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

    著者: Sandrine Faivre, Armando Santoro, Robin Kate Kelley, Ed Gane, Charlotte Costentin, Ivelina Gueorguieva, Claire Smith, Ann Cleverly, Michael Lahn, Éric Raymond, Karim A. Benhadji, Gianluigi Giannelli - Liver International 2019 被引用: 143

  8. Oxaliplatin: A review of preclinical and clinical studies

    著者: Éric Raymond, Stephen G. Chaney, A. Taamma, Esteban Cvitkovic - Annals of Oncology 1998 被引用: 636

  9. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

    著者: Rocio García‐Carbonero, Halfdan Sørbye, Éric Baudin, Éric Raymond, Bertram Wiedenmann, Bruno Niederle, Eva Sedláčková, Christos Toumpanakis, Martin Anlauf, Jarosław B. Ćwikła, Martyn Caplin, Dermot O’Toole, Aurel Perren, all other Vienna Consensus Conference participants - Neuroendocrinology 2016 被引用: 606

  10. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    著者: Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin, Joong‐Won Park, Masatoshi Kudo, Shukui Qin, Hyun Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi, Masao Omata, Susan Pitman Lowenthal, Silvana Lanzalone, Liqiang Yang, María José Lechuga, Éric Raymond - Journal of Clinical Oncology 2013 被引用: 774

  11. Molecular basis for sunitinib efficacy and future clinical development

    著者: Sandrine Faivre, George D. Demetri, William Q. Sargent, Éric Raymond - Nature Reviews Drug Discovery 2007 被引用: 712

  12. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

    著者: Christophe Le Tourneau, Éric Raymond, Sandrine Faivre - Therapeutics and Clinical Risk Management 2007 被引用: 242

  13. MEK in cancer and cancer therapy

    著者: Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Louis de Mestier, Jérôme Cros, Sandrine Faivre, Éric Raymond - Pharmacology & Therapeutics 2013 被引用: 265

  14. Current development of mTOR inhibitors as anticancer agents

    著者: Sandrine Faivre, Guido Kroemer, Éric Raymond - Nature Reviews Drug Discovery 2006 被引用: 995

  15. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

    著者: Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assénat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratté, Éric Raymond, Émilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne‐Laure Clairet, Christine Fagnoni-Legat, Olivier Adotévi, Aurélia Meurisse, Déwi Vernerey, Christophe Borg - BMC Cancer 2023 被引用: 22

  16. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

    著者: Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo L. Bello, Samuel E. DePrimo, Nicoletta Brega, Giorgio Massimini, Jean‐Pierre Armand, P. Scigalla, Éric Raymond - Journal of Clinical Oncology 2005 被引用: 1,154

  17. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

    著者: Lucile Astorgues‐Xerri, María E. Riveiro, Annemilaï Tijeras‐Raballand, Maria Serova, Gabriel A. Rabinovich, Ivan Bièche, Michel Vidaud, Armand de Gramont, Mathieu Martinet, Esteban Cvitkovic, Sandrine Faivre, Éric Raymond - European Journal of Cancer 2014 被引用: 137

  18. First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers

    著者: James J. Harding, Ahmad Awada, Gaël S. Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Christelle Ansaldi, Madani Rachid, Soraya Mezouar, Agnes Menut, Eloïne Bestion, Valérie Paradis, Philippe Halfon, Ghassan K. Abou‐Alfa, Éric Raymond - Liver Cancer 2022 被引用: 30

  19. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

    著者: Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence, Catherine Delbaldo, Karina Vera, Véronique Girre, Judy H. Chiao, Sian Armour, Sheelagh Frame, Simon R. Green, Athos Gianella-Borradori, Véronique Dièras, Éric Raymond - European Journal of Cancer 2010 被引用: 167

  20. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas

    著者: Stéphane Goutagny, Éric Raymond, Marina Esposito‐Farèse, Stéphanie Trunet, Christian Mawrin, Danièle Bernardeschi, Béatrice Larroque, Olivier Sterkers, Marco Giovannini, Michel Kalamarides - Journal of Neuro-Oncology 2015 被引用: 118

  21. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

    著者: Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, I. Bazin, Elena Poddubskaya, Nebojša Manojlović, Dejan Radenković, Chris Verslype, Éric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel - International Journal of Cancer 2018 被引用: 105

  22. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials

    著者: Laurent Meijer, Éric Raymond - ChemInform 2003 被引用: 350

  23. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

    著者: Sandrine Faivre, Patricia Niccoli, Daniel Castellano, Juan W. Valle, Pascal Hammel, Jean‐Luc Raoul, Aaron I. Vinik, Eric Van Cutsem, Yu Jeong Bang, Seung‐Hoon Lee, Ivan Borbath, Catherine Lombard‐Bohas, Peter Metrakos, Denis Smith, J.-S. Chen, Philippe Ruszniewski, Jean‐François Seitz, Shem Patyna, Dongrui R. Lu, K. Jack Ishak, Éric Raymond - Annals of Oncology 2016 被引用: 192

  24. Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding

    著者: Ruud P.M. Dings, Michelle C. Miller, Irina V. Nesmelova, Lucile Astorgues‐Xerri, Nigam Kumar, Maria Serova, Xuimei Chen, Éric Raymond, Thomas R. Hoye, Kevin H. Mayo - Journal of Medicinal Chemistry 2012 被引用: 133